Boundless Bio, Inc. (BOLD): Total Liabilities
$58.41M
As of 2025-12-31
$7.77M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.41M | +4.7% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $55.77M | +495.9% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $9.36M | n/a | 2025-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $58.41M | +4.7% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Veradermics, Inc (MANE) | 2025-12-31 | $9.16M | +94.1% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $10.52M | +12.9% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $9.68M | -31.3% |
Compare BOLD, PGEN, XLO, AQST side by side · Screen every company in Pharmaceutical Preparations ↗